Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Vivos Therapeutics ( (VVOS) ) has provided an announcement.
On May 21, 2025, Vivos Therapeutics, Inc. secured a convertible promissory note of $1,100,000 from V-Co Investors 2 LLC to support its acquisition of The Sleep Center of Nevada, expected to close by July 31, 2025. The note includes a $100,000 financing fee and provisions for conversion into equity upon a subsequent financing, with specific terms in case of default, highlighting strategic financial maneuvers to enhance its operational capabilities.
The most recent analyst rating on (VVOS) stock is a Buy with a $6.60 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.
Spark’s Take on VVOS Stock
According to Spark, TipRanks’ AI Analyst, VVOS is a Neutral.
Vivos Therapeutics faces significant financial challenges with ongoing losses and cash flow issues. While strategic shifts and potential acquisitions could offer growth opportunities, current financial instability and bearish technical indicators limit immediate upside potential. The stock’s valuation remains unattractive due to negative profitability metrics. Investors should be cautious due to high leverage and integration risks associated with strategic changes.
To see Spark’s full report on VVOS stock, click here.
More about Vivos Therapeutics
Vivos Therapeutics, Inc. operates in the healthcare industry, focusing on therapeutic solutions. The company is involved in the acquisition of The Sleep Center of Nevada to expand its market presence.
Average Trading Volume: 108,409
Technical Sentiment Signal: Sell
Current Market Cap: $12.31M
See more data about VVOS stock on TipRanks’ Stock Analysis page.